Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported ($5.19) EPS for the quarter, missing the consensus estimate of ($3.71) by ($1.48), FiscalAI reports.
Aptevo Therapeutics Price Performance
APVO stock opened at $0.55 on Tuesday. The stock has a 50-day moving average price of $1.57 and a two-hundred day moving average price of $3.97. Aptevo Therapeutics has a 12-month low of $0.55 and a 12-month high of $25.65.
Analysts Set New Price Targets
Separately, Weiss Ratings lowered shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Thursday, October 29th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has a consensus rating of “Sell”.
Get Our Latest Research Report on Aptevo Therapeutics
Aptevo Therapeutics Company Profile
Aptevo Therapeutics is a biotechnology company focused on developing immunotherapies, particularly treatments for cancer. Its research uses engineered antibody-based approaches intended to direct or activate the immune system against disease. The company’s programs have included APVO436, a bispecific antibody designed to connect CD3-positive T cells with CD123-positive leukemia cells and investigated as a potential treatment for acute myeloid leukemia. Aptevo has also worked on other immune-targeting candidates, including programs designed to stimulate immune responses against tumors.
Read More
- Five stocks we like better than Aptevo Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
